Patient and Family Care
Developing novel cell therapies to transform every aspect of the bone marrow transplant journey
Orca Bio is a values-based company, deeply rooted in the principles of science and innovation and dedicated to transforming new ideas and discoveries into medicines for patients with serious illnesses. We founded Orca Bio on the belief that there is a more effective and compassionate way to target blood cancer and decrease transplant related mortalities. We put the needs of patients, families and healthcare providers at the center of everything we do.
Our Clinical Studies
We are conducting a large multi-center Phase 1 study for our most recent clinical-stage program, OGFT-001, a fully engineered donor graft derived from mobilized peripheral blood.
Our most advanced clinical-stage program is TRGFT-201, a partially engineered and enriched donor graft for recipients undergoing allogeneic HSCTs for hematologic malignancies, currently being investigated as part of a Phase 1b study.